171 Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer

Similar Items

• Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade
  by: Haoxiao Zuo, et al.
  Published: (2021-11-01)
• P1383: STRONG AND SELECTIVE EX VIVO EXPANSION OF ADAPTIVE NKG2C+/CD57+ NK CELLS FROM CMV SEROPOSITIVE DONORS USING DENDRITIC CELLS DERIVED FROM THE LEUKEMIC CELL LINE DCONE AS FEEDER CELLS.
  by: Haoxiao Zuo, et al.
  Published: (2023-08-01)
• Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.
  by: Akiko Sumi, et al.
  Published: (2015-01-01)
• 672 Induction of specific T-cell responses to tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel
  by: Marco de Bruyn, et al.
  Published: (2023-11-01)
• CREATING DCP WORKFLOW FOR DIGITAL CINEMA SYSTEM
  by: Andreja SAMČOVIĆ
  Published: (2020-12-01)